This volume focuses on various aspects of interleukin-27 (IL-27),
especially its potential for clinical applications. The authors discuss
the downstream signaling from the IL-27 receptor and its molecular
targets in immune cells including Th1, Th2, Th17, Treg, Tr1, Tfh, B
cells, DCs and macrophages. The inhibition of Th17 cells by IL-27 is
vital for the maintenance of the feto-maternal tolerance and the
prevention of lupus, multiple sclerosis, autoimmune uveitis, immune
thrombocytopenia and atherosclerosis. However, the same inhibitory
capabilities compromise the immune response to bacterial pathogens, and
IL-27 is a pathogenic factor in sepsis and tuberculosis. Also covered
are the conflicting reports on the role of IL-27 in rheumatoid
arthritis, the effect of IL-27 on epithelia, which seems to play a role
in asthma, psoriasis and inflammatory bowel diseases, and the direct
cytotoxic and anti-vascular effects of IL-27, which make it a promising
agent for the treatment of cancer. Accordingly, this volume will be of
interest to researchers and clinicians alike.